Findings From the First-in-Human Phase 1 Trials of NX-2127 and NX-5948, Bruton’s Tyrosine Kinase (BTK) Degraders, in Patients with Relapsed/Refractory B-Cell Malignancies
Thursday, March 21, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix has initiated first-in-human Phase 1 trials for NX-2127 and NX-5948, which are Bruton’s Tyrosine Kinase (BTK) degraders targeting relapsed/refractory B-cell malignancies. The trials aim to assess the safety and efficacy of these novel therapies. Further insights into the trials and their potential impact on cancer treatment are anticipated.
Price reaction · baseline $13.28 (2024-03-20 close) · hit after-hours · 1 other NRIX headline(s) in the window, move may be shared
day 0 close · peak
-2%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.